Plastic Surgeon’s Risk Acceptance in Facial Transplantation
Authors:
- Christopher C. ReynoldsCRChristopher C. Reynolds
- Michael CunninghamMCMichael Cunningham
- Allen FurrAFAllen Furr
- Barckley StoreyBSBarckley Storey
- Joseph C. BanisJBJoseph C. Banis
- Osborne WigginsOWOsborne Wiggins
- Claudio MaldonadoCMClaudio Maldonado
- Rita R. AllowayRARita R. Alloway
- Moshe KonMKMoshe Kon
- John H. BarkerJBJohn H. Barker
- 1 March 2008
- journal article
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 121 (3) , 41e-48e
Abstract
A great deal of ethical debate has accompanied the introduction of facial tissue allotransplantation into the clinical arena. Critics contend that the risks of lifelong immunosuppression do not justify the benefits of this new non-life-saving reconstructive procedure, whereas proponents argue that they do. Absent from this debate are the opinions of individuals with real-life experiences with the risks and benefits associated with this new treatment.In this study, the authors question facially disfigured individuals (n = 33) and the reconstructive surgeons who treat them (n = 45), organ transplant recipients (n = 42) and the professionals who manage their immunosuppression medication (n = 37), and healthy volunteer controls (n = 148) to determine the amount of risk they are willing to accept to receive facial tissue allotransplantation. A survey with psychometrically reliable and validated questions was administered to the above five groups, and appropriate statistical analysis was used to analyze and compare the data within and between groups.Of the five groups studied, reconstructive surgeons would accept the least amount of risk for a facial tissue allotransplant, followed by transplant specialists, then kidney transplant recipients, then facially disfigured individuals, and finally healthy control volunteers, who would accept the most amount of risk.The authors' data indicate that reconstructive surgeons are the least tolerant of risks compared with the other groups studied concerning facial tissue allotransplantation. This is particularly important because they are the primary caregivers to facially disfigured patients and, as such, will be the ones to lead the effort to move this new reconstructive treatment into the clinical arena.Keywords
This publication has 22 references indexed in Scilit:
- First human face allograft: early reportThe Lancet, 2006
- On the Ethics of Composite Tissue Allotransplantation (Facial Transplantation)Plastic and Reconstructive Surgery, 2006
- The International Registry on Hand and Composite Tissue TransplantationTransplantation, 2005
- Facing OurselvesThe American Journal of Bioethics, 2004
- THE SPECTRUM OF COMPLICATIONS OF IMMUNOSUPPRESSIONJournal of Bone and Joint Surgery, 2002
- Concerns about human hand transplantation in the 21st centuryThe Journal of Hand Surgery, 2002
- Hand transplantation—primum non nocereThe Journal of Hand Surgery, 2002
- Successful Hand Transplantation — One-Year Follow-upNew England Journal of Medicine, 2000
- Hand transplantation: Comparisons and observations of the first four clinical casesMicrosurgery, 2000
- Human hand allograft: report on first 6 monthsThe Lancet, 1999